CN104587455A - Insulin preparation - Google Patents
Insulin preparation Download PDFInfo
- Publication number
- CN104587455A CN104587455A CN201310527159.4A CN201310527159A CN104587455A CN 104587455 A CN104587455 A CN 104587455A CN 201310527159 A CN201310527159 A CN 201310527159A CN 104587455 A CN104587455 A CN 104587455A
- Authority
- CN
- China
- Prior art keywords
- insulin
- solution
- preparation
- lispro
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 70
- 102000004877 Insulin Human genes 0.000 title claims abstract description 38
- 108090001061 Insulin Proteins 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 229940125396 insulin Drugs 0.000 title claims abstract description 35
- 108010065920 Insulin Lispro Proteins 0.000 claims abstract description 35
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 claims abstract description 35
- 229960002068 insulin lispro Drugs 0.000 claims abstract description 35
- 108010057186 Insulin Glargine Proteins 0.000 claims abstract description 34
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 claims abstract description 34
- 229960002869 insulin glargine Drugs 0.000 claims abstract description 34
- 239000000243 solution Substances 0.000 claims abstract description 33
- 238000002347 injection Methods 0.000 claims abstract description 29
- 239000007924 injection Substances 0.000 claims abstract description 29
- 239000002994 raw material Substances 0.000 claims abstract description 15
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 39
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 18
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 13
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims description 13
- 229940100630 metacresol Drugs 0.000 claims description 13
- 239000011701 zinc Substances 0.000 claims description 13
- 229910052725 zinc Inorganic materials 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 239000011787 zinc oxide Substances 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 7
- 230000003020 moisturizing effect Effects 0.000 claims description 7
- 230000002378 acidificating effect Effects 0.000 claims description 6
- -1 37.04mg Chemical compound 0.000 claims description 4
- 230000008901 benefit Effects 0.000 claims description 4
- YVZLYNHKJASIHA-UHFFFAOYSA-L [Na+].[K+].OP(O)([O-])=O.OP(O)([O-])=O Chemical compound [Na+].[K+].OP(O)([O-])=O.OP(O)([O-])=O YVZLYNHKJASIHA-UHFFFAOYSA-L 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 13
- 230000003203 everyday effect Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 108010092217 Long-Acting Insulin Proteins 0.000 abstract description 2
- 102000016261 Long-Acting Insulin Human genes 0.000 abstract description 2
- 239000000654 additive Substances 0.000 abstract description 2
- 239000003381 stabilizer Substances 0.000 abstract description 2
- 229940100066 Long-acting insulin Drugs 0.000 abstract 1
- 239000003124 biologic agent Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 11
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- 108010007568 Protamines Proteins 0.000 description 7
- 102000007327 Protamines Human genes 0.000 description 7
- 229940048914 protamine Drugs 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- 208000008630 Sialorrhea Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000892865 Heros Species 0.000 description 1
- 108010081368 Isophane Insulin Proteins 0.000 description 1
- 102000005237 Isophane Insulin Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the field of biological agents and especially relates to an insulin preparation. Multitime injection of different insulin injections each day brings inconvenience for diabetics. The insulin preparation solves the above problem, is a quick-acting and long-acting insulin mixture and is needed once every day thereby preventing multitime injection puzzle. The disclosed insulin preparation is obtained by mixing an insulin glargine solution and an insulin lispro solution. The insulin preparation is prepared from insulin glargine and insulin lispro as raw materials, is a clinical insulin preparation which can be stabilized only by pH condition and an phenol stabilizing agent without overmuch additives, simplifies a production technology, saves a production cost and further improves clinical use safety.
Description
Technical field
The present invention relates to field of biological, particularly relate to a kind of insulin preparation.
Background technology
In recent years, along with factors such as the change of growth in the living standard, dietary structure, the rhythm of life be becoming tight day, aged tendency of population and few dynamic life style of sitting more, whole world onset diabetes rate rapid development, and age of onset rejuvenation increasingly, diabetes have become the chronic disease of the third-largest serious threat human health after tumor, cardiovascular pathological changes.According to IDF (International Diabetes Federation) data, expecting the year two thousand thirty whole world has diabetics number to press on towards 500,000,000.
Although along with the development of science and technology and the progress of medical skill, Remedies for diabetes also continues to bring out, insulin and analog thereof the function and position in treating diabetes can not be substituted.At present, the treatment suggestion of diabetes (I type and type Ⅱdiabetes mellitus) adopts so-called strengthening insulin treatment, namely adopts multiple analgesic composition.According to this scheme, diabetics need be treated with the regular iletin that multiple injection is different every day, comprise once a day or double injection protamine zine insulin to meet the demand of basal insulin, supplement in addition and inject Semilente Insulin to meet the demand of Related Insulin after the meal.And diabetics wants insulinize many decades usually, in order to safety and quality of life, be starved of improvement analgesic composition, although also have analgesic composition to occur at present, be mostly PI or protamine zinc insulin.This is because think that protamine right and wrong are immunogenic in the early time, but find now that PI crystallization may have immunogenicity in human body, for antibody can be caused during medical object to be formed, some patients must avoid using the protamine zine insulin compositions containing protamine.Therefore we study fast and the combination of protamine zine insulin at this, while avoiding using protamine, improve the quality of life of diabetics.
Summary of the invention
The present invention live the inconvenience brought to diabetics in view of the different regular iletin of multiple injection every day, provides a kind of quick-acting and protamine zine insulin mixture, only needs injection every day once, avoid the puzzlement of multiple injection.
Technical scheme provided by the present invention is as follows:
Insulin preparation disclosed by the invention is mixed by insulin Glargine solution and insulin lispro solution.
Further, we also disclosed described insulin Glargine solution to be made up of a or several parts of insulin Glargine premix zoariums, a copy of it insulin Glargine premix zoarium is made up of at acidic injectable water, 300 μ g zinc ioies, metacresol 27mg, the glycerol 170mg of 3.5 ~ 4.5 37.04mg insulin Glargine raw material, 10ml pH.
Simultaneously, we also disclosed described insulin lispro solution to be made up of a or several parts of insulin lispro premix zoariums, a copy of it insulin lispro premix zoarium is made up of at acidic injectable water, 300 μ g zinc ioies, phenol 5mg, metacresol 27mg, the glycerol 170mg of 6.5 ~ 7.5 35.71mg insulin lispro raw material, 10ml pH.
Further, in the composition of insulin lispro solution, we also disclosed described pH 6.5 ~ 7.5 acidic injectable water be by sodium hydrogen phosphate-potassium dihydrogen phosphate buffer system, and dilute hydrochloric acid and sodium hydroxide solution regulate formation jointly.
Further, we also disclosed described insulin preparation and mixed by the insulin Glargine solution of 70 parts and the insulin lispro solution of 30 parts, the whole pH of described insulin preparation is 3.5 ~ 4.5.
Meanwhile, we also disclosed a kind of preparation method of insulin preparation disclosed in this invention, specifically comprise the following steps:
Steps A: take insulin Glargine raw material 1000IU by the content precision of insulin Glargine, i.e. 37.04mg, add injection water 4ml to stir, drip 0.1mol/L hydrochloric acid to dissolve completely to insulin Glargine, add in zinc oxide to every 100IU insulin glargine injecta containing zinc 30 μ g, then glycerol 170mg is added, metacresol 27mg, be stirred to benefit after all dissolving and add water to 9ml, then use 1mol/L hydrochloric acid solution or 1mol/L sodium hydroxide solution adjust ph to 3.5-4.5, moisturizing to final volume is 10ml, carries out filtration sterilization with 0.22 micrometer Millipore filter membrane;
Step B: take insulin lispro raw material 1000IU by the content precision of insulin lispro, i.e. 35.71mg, add injection water 4ml to stir, drip 0.1mol/L hydrochloric acid to dissolve completely to insulin lispro, add in zinc oxide to every 100IU Insulin Lispro Injection and contain zinc 30 μ g, then add glycerol 170mg, phenol 5mg, metacresol 27mg, be stirred to after all dissolving and add buffer, described buffer is containing 1.5mg/mlNa2HPO4,1.25mg/mlKH
2pO
4, to overall solution volume 9ml, then use 1mol/L hydrochloric acid solution or 1mol/L sodium hydroxide solution adjust ph to 6.5-7.5, moisturizing to final volume is 10ml, carries out filtration sterilization with 0.22 micrometer Millipore filter membrane;
According to steps A product: the ratio that step B product calculates 70:30 with volume ratio mixes, regulate pH to 3.5-4.5, obtain insulin preparation.
Insulin preparation disclosed in this invention with insulin lispro and insulin Glargine for raw material, when without the need to adding too much additive, only just can obtain stably insulin clinical practice system with pH condition and phenol stabilizer, thus not only simplify production technology, saved production cost, also further increase clinical use safety degree simultaneously.
Accompanying drawing explanation
Fig. 1 is the blood sugar concentration-time graph after the formulation samples of Beagle dog subcutaneous injection embodiment 1 preparation;
Fig. 2 is the blood sugar concentration-time graph after the formulation samples of Beagle dog subcutaneous injection embodiment 2 preparation.
Detailed description of the invention
Embodiment 1
First product A in the middle of preparation: take insulin Glargine raw material 1000IU(37.04mg by the content precision of insulin Glargine), add injection water 4ml to stir, drip 0.1mol/L hydrochloric acid to dissolve completely to insulin Glargine, add in zinc oxide to every 100IU insulin glargine injecta containing zinc 30 μ g, then glycerol 170mg is added, metacresol 27mg, is stirred to benefit after all dissolving and adds water to 10ml, carry out filtration sterilization with 0.22 micrometer Millipore filter membrane.
Then product B in the middle of preparation: take insulin lispro raw material 1000IU(35.71mg by the content precision of insulin lispro), add injection water 4ml to stir, drip 0.1mol/L hydrochloric acid to dissolve completely to insulin lispro, add in zinc oxide to every 100IU Insulin Lispro Injection containing zinc 30 μ g, then glycerol 170mg is added, phenol 5mg, metacresol 27mg, be stirred to after all dissolving and add buffer (containing 1.5mg/mlNa2HPO4,1.25mg/mlKH2PO4) to 10ml, carry out filtration sterilization with 0.22 micrometer Millipore filter membrane.
Finally, as required by middle product A: middle product B mixes with the ratio of volume ratio 70:30, and regulates pH to 3.5-4.5.
Embodiment 2
First product A in the middle of preparation: take insulin Glargine raw material 1000IU(37.04mg by the content precision of insulin Glargine), add injection water 4ml to stir, drip 0.1mol/L hydrochloric acid to dissolve completely to insulin Glargine, add in zinc oxide to every 100IU insulin glargine injecta containing zinc 30 μ g, then glycerol 170mg is added, metacresol 27mg, be stirred to benefit after all dissolving and add water to 9ml, then use 1mol/L hydrochloric acid solution or 1mol/L sodium hydroxide solution adjust ph to 3.5-4.5, moisturizing to final volume is 10ml, filtration sterilization is carried out with 0.22 micrometer Millipore filter membrane.
Then product B in the middle of preparation: take insulin lispro raw material 1000IU(35.71mg by the content precision of insulin lispro), add injection water 4ml to stir, drip 0.1mol/L hydrochloric acid to dissolve completely to insulin lispro, add in zinc oxide to every 100IU Insulin Lispro Injection containing zinc 30 μ g, then glycerol 170mg is added, phenol 5mg, metacresol 27mg, be stirred to after all dissolving and add buffer (containing 1.5mg/mlNa2HPO4, 1.25mg/mlKH2PO4) to 9ml, then use 1mol/L hydrochloric acid solution or 1mol/L sodium hydroxide solution adjust ph to 3.5-4.5, moisturizing to final volume is 10ml, filtration sterilization is carried out with 0.22 micrometer Millipore filter membrane.
Finally, as required by middle product A: middle product B mixes with the ratio of volume ratio 70:30.
Comparative example
Insulin Glargine raw material 700IU(25.93mg is taken respectively) according to the content precision of insulin Glargine and insulin lispro, insulin lispro 300IU(10.71mg) add injection water 4ml and stir, drip 0.1mol/L hydrochloric acid to dissolve completely to insulin lispro and insulin Glargine, add in zinc oxide to every 100IU regular iletin containing zinc 30 μ g, then glycerol 170mg is added, phenol 5mg, metacresol 27mg, be stirred to after all dissolving and add buffer (containing 1.5mg/mlNa
2hPO
4, 1.25mg/mlKH
2pO
4) to 9ml, then use 1mol/L hydrochloric acid solution or 1mol/L sodium hydroxide solution adjust ph to 3.5-4.5, moisturizing to final volume is 10ml, carries out filtration sterilization with 0.22 micrometer Millipore filter membrane.
Embodiment 3 study on the stability
Embodiment 3-1 gets each 10 samples of injection prepared by above often kind of method, observe its Apparent character after the centrifugal certain hour of 12000rpm: namely centrifugal rear taking-up sample observation bottom it with or without precipitation, record quantity, the sample of preparation method of the same race occur precipitation or floccule quantity fewer, illustrate that formulation samples prepared by the method is more stable.
Table 1 centrefuge experiment
| Sample | There is precipitation number in centrifugal 30min | There is precipitation number in centrifugal 60min |
| Embodiment 1 | 0 | 0 |
| Embodiment 2 | 0 | 0 |
| Comparative example 1 | 0 | 2 |
Embodiment 3-2
Get each 10 samples of injection prepared by above often kind of method after 4 DEG C of storage set times, after opening, room temperature observes its character after placing certain hour: occur that insoluble matter, floccule quantity are fewer, illustrate that preparation prepared by this preparation method is more stable.
The apparent study on the stability of table 2
| Sample | Place 10 days existing insoluble matter sample numbers | Place 20 days existing insoluble matter sample numbers | Place 30 days existing insoluble matter sample numbers |
| Embodiment 1 | 0 | 0 | 0 |
| Embodiment 2 | 0 | 0 | 0 |
| Comparative example | 1 | 5 | 7 |
Above result is known, the formulation samples storage set time prepared by example 1 and example 2, and after opening, room temperature places the Apparent character of certain hour without significant change, and stability is better.
Embodiment 4 shelf-stability is investigated
The storage of samples of the acquisition in Example 1 and embodiment 2, at 4 DEG C of certain hours, after unlatching, continues 4 DEG C of placements, detects its character, pH, macromolecule protein, related substance and content as following table respectively at sampling in 0,3,6,9 day:
Table 34 DEG C of shelf-stability tests
Formulation samples prepared by embodiment 1 and embodiment 2 is opened latter 4 DEG C and is placed 0,3,6,9 day, and its character, pH value, macromolecule protein, related substance and content, all without significant change, have good stability.
Embodiment 5 animal allergic test
Formulation samples prepared by Example 1 and embodiment 2 carries out the research of animal sensitization type respectively: namely get 18 Beagle dogs, when administration starts, body weight is 7.0-11.2kg, be divided into 3 groups at random according to sex, body weight, often organize each 3 heros 3 female, be respectively matched group, embodiment 1 group and embodiment 2 groups.The normal saline of matched group injection equivalent, other are the group corresponding sample injected corresponding embodiment and obtain respectively respectively, every treated animal gives 1.5IU/kg through neck dorsal sc injection respectively simultaneously, successive administration 7 days, once a day, after observation per injection, whether the reaction of each dog, namely occur that there are erythema, edematous condition in injection site, observe anaphylaxiss such as whether having edema, sialorrhea, nausea,vomiting,diarrhea simultaneously.
Result of study finds, during the administration of all Beagle dogs, does not all find that there are erythema, edema, the obviously abnormal conditions such as hemorrhage in injection site, does not also occur the anaphylaxiss such as edema, sialorrhea, nausea,vomiting,diarrhea after injection.Therefore, illustrate that the product clinical safety that the present invention obtains is good, there is higher clinical value.
Embodiment 6 pharmacodynamic experiment
Get adult healthy Beagle dog 6 respectively, male and female half and half, female without pregnant, at the 7-9 monthly age, body weight 9.6-12.5kg, forms embodiment 1 experimental group and embodiment 2 experimental group.The sample for preparing of subcutaneous injection embodiment 1, embodiment 2 respectively, before administration, different time gets blood from Beagle dog foreleg vein, get before blood time point is respectively 0h(administration), 1h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h, 24h, get blood 2mL at every turn, 4 DEG C, separated plasma after the centrifugal 10min of 3500rpm, carry out glucose concentration determination, draw different time blood sugar concentration variation diagram, result respectively as depicted in figs. 1 and 2.
Can find out that insulin preparation disclosed by the invention has long-acting, efficient hypoglycemic activity.
Claims (6)
1. an insulin preparation, is characterized in that: described insulin preparation is mixed by insulin Glargine solution and insulin lispro solution.
2. insulin preparation according to claim 1, it is characterized in that: described insulin Glargine solution is made up of a or several parts of insulin Glargine premix zoariums, a copy of it insulin Glargine premix zoarium is made up of at acidic injectable water, 300 μ g zinc ioies, metacresol 27mg, the glycerol 170mg of 3.5 ~ 4.5 37.04mg insulin Glargine raw material, 10ml pH.
3. insulin preparation according to claim 1, it is characterized in that: described insulin lispro solution is made up of a or several parts of insulin lispro premix zoariums, a copy of it insulin lispro premix zoarium is made up of at acidic injectable water, 300 μ g zinc ioies, phenol 5mg, metacresol 27mg, the glycerol 170mg of 6.5 ~ 7.5 35.71mg insulin lispro raw material, 10ml pH.
4. insulin preparation according to claim 3, is characterized in that: described pH is by sodium hydrogen phosphate-potassium dihydrogen phosphate buffer system at the acidic injectable water of 6.5 ~ 7.5, and dilute hydrochloric acid and sodium hydroxide solution regulate formation jointly.
5. insulin preparation according to claim 1, is characterized in that: described insulin preparation is mixed by the insulin Glargine solution of 70 parts and the insulin lispro solution of 30 parts, and the whole pH of described insulin preparation is 3.5 ~ 4.5.
6. a preparation method for the insulin preparation in claim 1 to 5 described in any one, is characterized in that, comprises the following steps:
Steps A: take insulin Glargine raw material 1000IU by the content precision of insulin Glargine, i.e. 37.04mg, add injection water 4ml to stir, drip 0.1mol/L hydrochloric acid to dissolve completely to insulin Glargine, add in zinc oxide to every 100IU insulin glargine injecta containing zinc 30 μ g, then glycerol 170mg is added, metacresol 27mg, be stirred to benefit after all dissolving and add water to 9ml, then use 1mol/L hydrochloric acid solution or 1mol/L sodium hydroxide solution adjust ph to 3.5-4.5, moisturizing to final volume is 10ml, carries out filtration sterilization with 0.22 micrometer Millipore filter membrane;
Step B: take insulin lispro raw material 1000IU by the content precision of insulin lispro, i.e. 35.71mg, add injection water 4ml to stir, drip 0.1mol/L hydrochloric acid to dissolve completely to insulin lispro, add in zinc oxide to every 100IU Insulin Lispro Injection and contain zinc 30 μ g, then add glycerol 170mg, phenol 5mg, metacresol 27mg, be stirred to after all dissolving and add buffer, described buffer is containing 1.5mg/mlNa
2hPO
4, 1.25mg/mlKH
2pO4, to overall solution volume 9ml, then use 1mol/L hydrochloric acid solution or 1mol/L sodium hydroxide solution adjust ph to 6.5-7.5, moisturizing to final volume is 10ml, carries out filtration sterilization with 0.22 micrometer Millipore filter membrane;
According to steps A product: the ratio that step B product calculates 70:30 with volume ratio mixes, regulate pH to 3.5-4.5, obtain insulin preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310527159.4A CN104587455A (en) | 2013-10-31 | 2013-10-31 | Insulin preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310527159.4A CN104587455A (en) | 2013-10-31 | 2013-10-31 | Insulin preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104587455A true CN104587455A (en) | 2015-05-06 |
Family
ID=53113726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310527159.4A Pending CN104587455A (en) | 2013-10-31 | 2013-10-31 | Insulin preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104587455A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110087674A (en) * | 2016-12-16 | 2019-08-02 | 诺和诺德股份有限公司 | The pharmaceutical composition of insulin-containing |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101454019A (en) * | 2006-04-12 | 2009-06-10 | 百达尔公司 | Rapid acting and long acting insulin combination formulations |
| CN101951957A (en) * | 2008-01-04 | 2011-01-19 | 百达尔公司 | Insulin discharges the insulin preparation as the function of the glucose level of tissue |
| CN102199206A (en) * | 2011-03-17 | 2011-09-28 | 甘李药业有限公司 | Insulin analogue having quick response and stability under acidic condition and preparation thereof |
| CN102319422A (en) * | 2010-05-19 | 2012-01-18 | 赛诺菲-安万特 | long-acting insulin preparations |
| US20130178415A1 (en) * | 2012-01-09 | 2013-07-11 | Adocia | Injectable solution at pH 7 comprising at least one basal insulin the PI of which is between 5.8 and 8.5 and a substituted co-polyamino acid |
-
2013
- 2013-10-31 CN CN201310527159.4A patent/CN104587455A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101454019A (en) * | 2006-04-12 | 2009-06-10 | 百达尔公司 | Rapid acting and long acting insulin combination formulations |
| CN101951957A (en) * | 2008-01-04 | 2011-01-19 | 百达尔公司 | Insulin discharges the insulin preparation as the function of the glucose level of tissue |
| CN102319422A (en) * | 2010-05-19 | 2012-01-18 | 赛诺菲-安万特 | long-acting insulin preparations |
| CN102199206A (en) * | 2011-03-17 | 2011-09-28 | 甘李药业有限公司 | Insulin analogue having quick response and stability under acidic condition and preparation thereof |
| US20130178415A1 (en) * | 2012-01-09 | 2013-07-11 | Adocia | Injectable solution at pH 7 comprising at least one basal insulin the PI of which is between 5.8 and 8.5 and a substituted co-polyamino acid |
Non-Patent Citations (3)
| Title |
|---|
| LUCCHESI MBB ET AL.: "A 12-wk follow-up study to evaluate the effects of mixing insulin lispro and insulin glargine in young individuals with type 1 diabetes", 《PEDIATRIC DIABETES》 * |
| 张石革 陈瑞红: "胰岛素类似物的进展与优势", 《中国医药导刊》 * |
| 郭立新: "预混胰岛素的应用", 《药品评价》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110087674A (en) * | 2016-12-16 | 2019-08-02 | 诺和诺德股份有限公司 | The pharmaceutical composition of insulin-containing |
| CN115154591A (en) * | 2016-12-16 | 2022-10-11 | 诺和诺德股份有限公司 | Insulin-containing pharmaceutical composition |
| CN115154591B (en) * | 2016-12-16 | 2023-04-14 | 诺和诺德股份有限公司 | Pharmaceutical composition containing insulin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Anderson et al. | Suppression of insulin secretion by the growth hormone of the anterior pituitary as determined with the isolated rat pancreas in a perfusion apparatus | |
| CN102199206B (en) | Insulin analogue having quick response and stability under acidic condition and preparation thereof | |
| CAMPBELL et al. | Metahypophyseal diabetes produced by growth hormone | |
| CN104367987A (en) | Astragalus mongholicus formulation for veterinary use and preparation method thereof | |
| Tarail et al. | Hypoglycemic activity of tris buffer in man and dog | |
| Salvesen | Studies on the physiology of the parathyroids | |
| CN104587455A (en) | Insulin preparation | |
| CN101380329B (en) | Preparation method of arginine aspirin and powder and injection preparation thereof | |
| CN102247373A (en) | Composition of methionine vitamin B1 compound | |
| CN101623284A (en) | Medical composition of compound vitamin C injection | |
| CN102657606B (en) | Lipoic acid injection for intravenous administration | |
| CN102188367B (en) | Insulin glargine injecta and preparation method thereof | |
| CN101904856A (en) | Application of 1,6-diphosphofructose and derivative thereof in preparing animal medical health care products | |
| CN112717119A (en) | Cetrorelix pharmaceutical composition and preparation method thereof | |
| Best | Recent work on insulin | |
| CN102441160B (en) | Thymosin alpha1 medicinal composition and preparation method thereof | |
| CN105535942A (en) | Insulin lispro-protamine sulfate preparation and preparation method thereof | |
| CN105597087B (en) | A kind of insulin glargine injecta and preparation method thereof | |
| CN106729639B (en) | A kind of insulin glargine injecta and preparation method thereof | |
| RU2790575C1 (en) | Method for production of combined antihelminth drug for prevention and treatment of fish cestodiasis | |
| CN102178655B (en) | Preparation method of osteocalcin (OC) freeze-dried powder preparation for injection | |
| Rous et al. | STUDIES ON THE TOTAL BILE: II. THE RELATION OF CARBOHYDRATES TO THE OUTPUT OF BILE PIGMENT | |
| CN105267159A (en) | Matrine freeze-dried powder injection and preparation method thereof | |
| US2190137A (en) | Soluble protamine insulin | |
| Janes et al. | The influence of diethylstilbestrol on alloxan diabetes paired feeding experiments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150506 |